Challenges Facing Prostate Cancer Equity
Brandon Mahal, MD, discusses challenges facing prostate cancer equity.
Brandon Mahal, MD, an assistant professor at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses challenges facing prostate cancer equity.
According to Mahal, there are only 3 well-established prostate cancer risk factors: age, family history, and race. Mahal notes that while race is a social construct, the factors driving race such as culture and environmental influences are very real. They inform race, which creates the social structure.
In order to better understand prostate cancer risk factors, we must better understand race, according to Mahal. It shouldn’t be that race is the underlying driving factor, but what is driving race, such as the environment and structural racism. According to Mahal, physicians must themselves to understand the factors driving race. By doing so, the field will have better knowledge around what drives prostate cancer risk.
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More
Capivasertib Improves PFS in PTEN-Deficient mHSPC
November 30th 2024Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Read More
